Evidence map›Paper›PMID 36087301›Full record

ArticleJournal of clinical laboratory analysis2022

The DNAm levels of CREB5 (cg11301281) were associated with clopidogrel resistance.

Jiyi Li, Jin Yang, Qinglin Yu, Lian Chen, Xiliang Shi, Jia Su, Keqi Zhu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jiyi LiDepartment of Cardiology, Yuyao People's Hospital of Zhejiang Province, Ningbo, China.
Jin YangDepartment of Cardiology, Ningbo, China.
Qinglin YuDepartment of Traditional Chinese Internal Medicine, Ningbo, China.
Lian ChenDepartment of Cardiology, Yuyao People's Hospital of Zhejiang Province, Ningbo, China.
Xiliang ShiDepartment of Cardiology, Yuyao People's Hospital of Zhejiang Province, Ningbo, China.
Jia SuDepartment of Cardiology, Ningbo, China.ORCID https://orcid.org/0000-0003-2163-2739
Keqi ZhuDepartment of Traditional Chinese Internal Medicine, Ningbo, China.
Yuxian People's Hospital · CNUniversity of Nottingham Ningbo China · CN

Funding

Natural Science Foundation of Ningbo 2021J265Ningbo Municipal Public Welfare Project 2021S109the Project of Science and technology on Medicine and Health in Zhejiang Province 2022KY312the Project of Science and Technology on Traditional Chinese Medicine in Zhejiang Province 2022ZB322
6 · The paper itself

Abstract

purposeClopidogrel resistance (CR) is mostly caused by interindividual variability of the platelet inhibition of clopidogrel, which may induce cardiovascular events. The aim of this research was to evaluate whether DNAm levels of CREB5 (cg01534253) are involved in CR among acute coronary syndrome (ACS) patients treated with clopidogrel.

methods72 patients(36 CR and 36 non-CR) who underwent ACS were included in this study. The VerifyNow P2Y12 assay was selected to evaluate residual platelet reactivity, and bisulfite pyrosequencing methods was used to examine DNA methylation levels on cg01534253. Secondly, CREB5 mRNA expression was analyzed via quantitative real-time PCR. Last, we employed logistic regression to test the interaction between genetic factors of CREB5 methylation and multiple clinical variables in CR patients.

resultsSubunit analysis indicated that for patients whose HbA1c levels were ≥6.5% or whose GLU levels were ≥7 mmol/L, lower methylation of cg01534253 indicated a poorer clopidogrel response. In addition, CREB5 mRNA expression was increased in CR patients with GLU levels ≥7 mmol/L. Moreover, regression analysis indicated that the values of albumin and uric acid were correlated with the incidence of CR.

conclusionsOur findings were likely to provide fresh understanding for the new mechanism of platelet inhibition failure and promote individualized antiplatelet therapy.

Indexed as

Acute Coronary SyndromePlatelet Aggregation InhibitorsAlbuminsBlood PlateletsClopidogrelCyclic AMP Response Element-Binding Protein AGlycated HemoglobinHumansRNA, MessengerTiclopidineUric AcidAlbuminsClopidogrelCREB5 protein, humanCyclic AMP Response Element-Binding Protein AGlycated HemoglobinPlatelet Aggregation InhibitorsRNA, MessengerTiclopidineUric Acidclopidogrel resistanceCREB5DNA methylation

Identifiers

PMID36087301
PMCPMC9550965
OpenAlexW4295107334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.